Article thumbnail

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature

By Angela Y Moore and Blakely S Richardson

Abstract

Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis population. Treatment of this group is challenging due to the long-term side effects, toxicities and inconvenience of conventional treatments such as phototherapy, methotrexate and cyclosporine. However, recent advances in our understanding of the pathogenesis of psoriasis have led to the popular use of biologics, which offer a safer, more convenient and effective targeted therapy. Adalimumab was originally approved for treating rheumatoid arthritis. Currently, adalimumab is also approved for treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy or when other systemic therapies are medically less appropriate. Since the onset of the use of biologics, there have been concerns over safety and efficacy when used as long-term therapy. This paper reviews all publications, posters and abstracts reporting original data on the efficacy and/or safety of adalimumab in patients treated for chronic plaque psoriasis for more than 1 year

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3047941
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration Database.
  2. Acute generalized skin eruption due to adalimumab: report of two cases.
  3. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent.
  4. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis.
  5. (2007). Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum.
  6. Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics.
  7. (2005). Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.
  8. Adalimumab in dermatology.
  9. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis.
  10. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
  11. Adalimumab-associated optic neuritis.
  12. (2007). Adalimumab-induced cutaneous lupus. Clin Exp Dermatol.
  13. (2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum.
  14. (2005). Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis.
  15. (2001). C; on behalf of the BSR. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of
  16. (2005). Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum.
  17. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
  18. (2005). Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther.
  19. (2008). Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum.
  20. (2007). Drug-induced lupus erythematosus in a patient treated with adalimumab. J Am Acad Dermatol.
  21. (2006). Effect of adalimumab (HUMIRA®) on response to pneumococcal and influenza virus vaccines in patients with rheumatoid arthritis (RA). [poster] EULAR,
  22. (2008). Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs. placebo in patients with psoriasis
  23. (2008). Efficacy and safety results in patients with psoriasis treated continuously with adalimumab for 100 weeks.
  24. (2006). Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis.
  25. (2007). Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol.
  26. (2007). Flare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockers. Clin Exp Dermatol.
  27. From conventional to cutting edge: the new era of biologics in the treatment of psoriasis. Dermatol Ther.
  28. Guidelines of care for the management of psoriasis and psoriatic arthritis.
  29. Heart disease in psoriasis.
  30. (2008). How to manage infections in the era of biologics? Dermatol Ther.
  31. (2006). Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol.
  32. Long-term efficacy of adalimumab in generalized pustular psoriasis.
  33. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
  34. (2003). Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum.
  35. (2009). Pregnancy outcomes in women exposed to adalimumab. University of California,
  36. (2005). Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis.
  37. (2008). Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum.
  38. (2005). rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev.
  39. Risk of myocardial infarction in patients with psoriasis.
  40. Role of depression in quality of life for patients with psoriasis.
  41. (2006). Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing. Ann Rheum Dis.
  42. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
  43. (2008). Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2 years result from an open label extension study.
  44. (2008). Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol.
  45. T-Helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis.
  46. (2008). The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum.
  47. The impact of treatment with tumor necrosis factor-α antagonists on the curse of chronic viral infections: a review of the literature.
  48. The prevalence of previously diagnosed and undiagnosed psoriasis
  49. The risk of lymphoma in patients with psoriasis.
  50. (2007). The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol.
  51. (2008). Treating psoriasis with adalimumab. Ther Clin Risk Manag.
  52. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.